M-Scan is a world leading contract analytical laboratory providing specialised services to the pharmaceutical and biotechnology industries. We offer unrivalled GLP/GMP accredited facilities for analysis in the fields of Life Sciences (Biotechnology, Proteomics) and Pharmaceuticals (ADME/PK, impurity analysis etc). We have particular expertise in the structural characterisation of glycoproteins such as antibodies (including “Biosimilar” or “follow-on “products) to FDA and EMEA guidelines.
Founded in 1979, the M-Scan group now comprise four laboratories, in UK, USA, Switzerland and Germany, with marketing offices worldwide including Europe, India, Singapore and South Korea. Our FDA inspected laboratories are equipped with a range of over 20 high performance mass spectrometers and other high-end analytical equipment to study molecules at all stages of product development, including research, process QC and regulatory approval. Our experienced scientists can provide a complete protein and carbohydrate structural analytical package tailored to ICH Q6B requirements and guide you in your choice of appropriate methods.
ProGenosis is a biotechnology company dedicated to the determination of protein interactions with a primary focus is on receptor-ligand interactions. Our proprietary technology platform is geared to developing efficient, innovative and convenient Bifunctional Hybrid Proteins (BHPs), which can be used for protein domain studies. ProGenosis provides Life Science companies with R&D customized services in its core business field.
ProGenosis has developed a BHP expression platform which uses a very robust and efficient positive drug-based screening system dedicated to the easy and straightforward selection of fully soluble and well-folded proteins. The BHP technology could be cost efficiently used within Therapeutic Monoclonal antibodies (epitope-mapping, Mabies candidate generation, hybridoma screening) - Therapeutic proteins (difficult to express protein, GPCRs, ion channel) - Human vaccines development - Small molecule inhibitor therapeutics.
>
Visit ProGenosis
MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information and to consider career possibilities, visit MedImmune's website at
www.medimmune.com.
